Integra LifeSciences (NASDAQ:IART) Releases FY 2025 Earnings Guidance

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

Integra LifeSciences (NASDAQ:IART - Get Free Report) issued an update on its FY 2025 earnings guidance on Thursday morning. The company provided earnings per share guidance of 2.190-2.290 for the period, compared to the consensus earnings per share estimate of 2.240. The company issued revenue guidance of $1.7 billion-$1.7 billion, compared to the consensus revenue estimate of $1.7 billion. Integra LifeSciences also updated its Q3 2025 guidance to 0.400-0.450 EPS.

Integra LifeSciences Stock Down 6.3%

Shares of IART stock traded down $0.83 during mid-day trading on Friday, reaching $12.31. 2,230,460 shares of the company's stock traded hands, compared to its average volume of 1,037,569. Integra LifeSciences has a 12 month low of $11.06 and a 12 month high of $27.13. The company has a market cap of $956.61 million, a P/E ratio of -1.89, a P/E/G ratio of 0.69 and a beta of 1.16. The company's 50-day moving average price is $12.60 and its 200-day moving average price is $17.63. The company has a quick ratio of 0.72, a current ratio of 1.21 and a debt-to-equity ratio of 0.81.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last released its earnings results on Thursday, July 31st. The life sciences company reported $0.45 EPS for the quarter, topping analysts' consensus estimates of $0.43 by $0.02. Integra LifeSciences had a positive return on equity of 11.18% and a negative net margin of 30.87%. The firm had revenue of $415.61 million for the quarter, compared to analysts' expectations of $395.06 million. During the same period in the prior year, the firm posted $0.63 earnings per share. The company's quarterly revenue was down .6% on a year-over-year basis. On average, equities analysts expect that Integra LifeSciences will post 2.45 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

IART has been the topic of several recent analyst reports. JMP Securities dropped their price objective on Integra LifeSciences from $35.00 to $25.00 and set a "market outperform" rating on the stock in a research report on Friday, May 9th. Truist Financial dropped their price objective on Integra LifeSciences from $26.00 to $19.00 and set a "hold" rating on the stock in a research report on Friday, April 11th. Wells Fargo & Company decreased their price objective on Integra LifeSciences from $25.00 to $13.00 and set an "equal weight" rating on the stock in a research note on Tuesday, May 6th. Finally, JPMorgan Chase & Co. decreased their price objective on Integra LifeSciences from $24.00 to $12.00 and set an "underweight" rating on the stock in a research note on Tuesday, May 6th. Four equities research analysts have rated the stock with a sell rating, three have given a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Hold" and an average price target of $18.63.

Institutional Investors Weigh In On Integra LifeSciences

A number of institutional investors and hedge funds have recently modified their holdings of IART. Dynamic Technology Lab Private Ltd purchased a new position in Integra LifeSciences during the 1st quarter valued at $277,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in Integra LifeSciences by 5.1% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 40,441 shares of the life sciences company's stock valued at $889,000 after acquiring an additional 1,975 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in Integra LifeSciences by 23.0% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 244,335 shares of the life sciences company's stock valued at $5,373,000 after acquiring an additional 45,693 shares during the period. Finally, Goldman Sachs Group Inc. raised its position in Integra LifeSciences by 2.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,660,511 shares of the life sciences company's stock valued at $36,515,000 after purchasing an additional 35,790 shares in the last quarter. 84.78% of the stock is owned by institutional investors.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.